

Association between Maternal Serum Perfluoroalkyl
Substances during Pregnancy and Maternal and Cord
Thyroid Hormones:
Taiwan Maternal and Infant Cohort Study

Yan Wang, Walter J. Rogan, Pau-Chung Chen, Guang-Wen Lien,
Hsiao-Yen Chen, Ying-Chih Tseng, Matthew P. Longnecker,
and Shu-Li Wang

<http://dx.doi.org/10.1289/ehp.1306925>

Received: 10 April 2013

Accepted: 20 February 2014

Advance Publication: 21 February 2014

Association between Maternal Serum Perfluoroalkyl Substances during Pregnancy and Maternal and Cord Thyroid Hormones: Taiwan Maternal and Infant Cohort Study

Yan Wang,¹ Walter J. Rogan,¹ Pau-Chung Chen,^{2,3,4} Guang-Wen Lien,² Hsiao-Yen Chen,⁵ Ying-Chih Tseng,⁶ Matthew P. Longnecker,¹ and Shu-Li Wang^{1,5,7}

¹Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, DHHS, Research Triangle Park, North Carolina, USA; ²Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health, Taipei, Taiwan; ³Department of Public Health, National Taiwan University College of Public Health, Taipei, Taiwan; ⁴Department of Environmental and Occupational Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan; ⁵Division of Environmental Health and Occupational Medicine, National Health Research Institutes, Miaoli, Taiwan; ⁶Department of Obstetrics and Gynecology, Hsinchu Cathay General Hospital, Hsinchu, Taiwan; ⁷Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan

Address correspondence to Shu-Li Wang, Division of Environmental Health and Occupational Medicine, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 350, Taiwan. Telephone: +886-37-246-166, ext. 36509. Fax: +886-37-587-406. E-mail:

slwang@nhri.org.tw

Running title: PFASs and Maternal and Cord Thyroid Hormones

Acknowledgments: We are greatly indebted to the clinics of the Department of Obstetrics and Gynecology and Department of Pediatrics, Chung-Shan Medical University Hospital, especially for the assistance of Dr. Tsung-Ho Ying, and Dr. Ben-Hua Su, respectively. We appreciate Ms. Angela Chingyu Chang and Carol Huichun Chen at the National Health Research Institutes, Miaoli, Taiwan, for subject recruitment, and data and specimen collections.

Funding: The study was funded by National Health Research Institutes, Taiwan (EO-101-PP-05, EH-102-SP-02, EO-102-PP-05), the National Science Council, Taiwan (NSC101-2325-B-400-008), and in part by the National Institute of Environmental Health Sciences, National Institutes of Health, USA.

Competing Financial Interests: The authors have declared that no competing interests exist.

Abstract

Background: Perfluoroalkyl substances (PFASs) are synthetic compounds that are widely used in industry and are often detectable in humans. In pregnant rats and their pups, PFASs can interfere with thyroid hormone homeostasis. In humans, maternal thyroid hormones supply the fetus throughout pregnancy, and thyroid hormones play a critical role in fetal growth and neurodevelopment.

Objectives: To investigate the association between maternal PFAS exposure and thyroid hormone status in pregnant women and neonates.

Methods: In a study of environmental exposure and health in Taiwan, we measured serum concentrations of 9 PFASs and 4 thyroid hormones for 285 pregnant women in their third trimester; and also measured cord serum thyroid hormones for 116 neonates. Associations between maternal PFASs and maternal and cord thyroid hormones were examined in multiple linear regression models.

Results: Perfluorohexanesulfonic acid concentrations were positively associated with maternal thyroid stimulating hormone (TSH) levels. Pregnant women with higher levels of perfluorononanoic acid (PFNA), perfluoroundecanoic acid (PFUnDA) and perfluorododecanoic acid (PFDoDA) had lower free thyroxine (T4) and total T4 levels. For example, we estimated that maternal free T4 levels decreased 0.019 ng/dL (-0.028, -0.009) with each ng/mL increase in maternal PFNA. Finally, maternal PFNA, PFUnDA, and PFDoDA levels were associated with lower cord total triiodothyronine (T3) and total T4 levels, and maternal perfluorodecanoic acid (PFDeA) was associated with lower cord total T3.

Conclusions: Our results suggest that exposure to some PFASs during pregnancy may interfere with thyroid hormone homeostasis in pregnant women and fetuses.

Introduction

Perfluoroalkyl substances (PFASs) are synthetic compounds that are heat resistant and chemically stable. They are widely used in commercial products, such as furniture, carpets, fire-fighting foams, food packing materials, and cooking utensils (Lau et al. 2007).

Several different pathways have been suggested by which humans are exposed to PFASs, including diet, drinking water, migration from packaged foods, indoor dust and outdoor air (Fromme et al. 2009). Some PFASs can accumulate in the environment and are often detectable in the tissues of humans (Houde et al. 2006). Long elimination half-lives have been observed for some PFASs in humans; for example, means of 4.8 years for perfluorooctane sulfonate (PFOS) and 3.5 years for perfluorooctanoic acid (PFOA) (Olsen et al. 2007). While PFOS and PFOA have been phased out by manufacturers, perfluorononanoic acid (PFNA) concentrations have increased in the environment and in the tissues of humans (Andersen et al. 2008; Calafat et al. 2007). The persistence and bioaccumulative properties of PFASs have raised concerns about exposure to PFASs and human health effects.

Experimental studies have found that PFOS treatment reduces total serum concentrations of thyroxine (T4) and triiodothyronine (T3) in pregnant rats (Chang et al. 2008; Luebker et al. 2005; Thibodeaux et al. 2003) and total T4 levels were reduced in PFOS treated rat pups (Lau et al. 2003; Luebker et al. 2005). In humans, Kim et al.'s recruited pregnant women from hospitals in three large cities in South Korea and analyzed 44 blood samples collected in the 3rd trimester and from the cord at delivery. Their results showed inverse correlations between maternal PFOS and cord T3 levels, inverse correlations between maternal perfluorotridecanoic acid (PFTrDA) and cord T4 and T3, and positive correlations between maternal PFOA and cord thyroid stimulating

hormone (TSH) levels after adjustment (Kim et al. 2011). However, a case-control study of Canadian pregnant women reported that serum concentrations of PFOA, PFOS and perfluorohexanesulfonic acid (PFHxS) were not associated with hypothyroxinemia (Chan et al. 2011).

Thyroid hormones are essential for normal fetal growth and development. The fetus is completely reliant on maternal T4 during the first trimester; thereafter, the fetal thyroid gland begins to function (Contempre et al. 1993; Vulsma et al. 1989). At birth, approximately 30% of T4 in cord blood originates from the mother (Fisher 1997). Therefore, both mothers and fetuses supply thyroid hormones during pregnancy. Concerns thus arise about the potential effect of *in utero* PFAS exposure on thyroid hormone homeostasis in pregnant women and their fetuses.

Our study was designed to examine possible associations between maternal serum concentrations of PFASs during pregnancy and 1) thyroid hormones in pregnant women, and 2) thyroid hormones in neonates.

Materials and Methods

Subjects and data collection

Our subjects were from a longitudinal birth cohort study of environmental exposures and health among pregnant women and children in central Taiwan, part of the nationwide Taiwan Maternal and Infant Cohort Study. From December 2000 to November 2001, we invited all pregnant women visiting the local medical centers to participate in the study. At their first visit in the obstetric clinic, we recruited 430 women and interviewed them about demographic factors, reproductive and medical histories, and diet during pregnancy. We collected blood samples during their third trimester and umbilical cord blood samples at delivery. Among 430 recruited

women, 135 had no measurement of either PFASs or thyroid hormones and 10 reported thyroid disease; they were excluded from the study. Thus, we had 285 subjects with data on both PFAS concentrations and thyroid hormones.

The Human Ethical Committee of the National Health Research Institutes in Taiwan approved the study. Each of the participants signed informed consent documents at the time of enrollment.

Exposure assessment

We sent maternal serum samples to National Taiwan University for measurement of PFASs. Altogether 9 PFASs were analyzed: PFHxS, PFOA, PFOS, PFNA, perfluorodecanoic acid (PFDeA), perfluoroundecanoic acid (PFUnDA), perfluorododecanoic acid (PFDoDA), perfluoroheptanoic acid (PFHpA), and perfluorohexanoic acid (PFHxA). The analytical method has been described elsewhere in detail (Lien et al. 2011; Lin et al. 2012). In this study, we modified the sample preparation procedure slightly. One hundred μL of plasma sample was vortexed with 100 μL of 1% formic acid ($\text{pH} = 2.8$) for 30 seconds. Then 250 μL of methanol and 50 μL of 0.01 ng/mL internal standard solution ($^{13}\text{C}_8$ -PFOA) were added to each sample before the second vortex. The mixture was sonicated for 20 minutes and then centrifuged at 14,000 rpm for 20 minutes. The supernatant was collected and then was filtered through a 0.22- μm PVDF syringe filter into a 2.0 mL auto-sampler vial.

Nine calibration standard solutions were prepared in 100 μL of bovine plasma and were prepared as described. The concentrations of specific analytes ranged from 0.25-125 ng/mL, with a fixed amount of internal standard (5 ng/mL).

The separation and detection were performed on an Agilent-1200 high performance liquid chromatography system (Agilent, Palo Alto, CA, USA) coupled with a triple-quadrupole mass

spectrometer (Sciex API 4000, Applied Biosystems, Foster City, CA, USA). The limits of quantitation (LOQs), defined as a signal-to-noise ratio of ten, ranged from 0.07 to 0.45 ng/mL for the nine PFASs. The intra-assay coefficients of variation (CVs) for PFAS concentrations ranged from 0.83 to 7.94% and the inter-assay CVs were 1.57 - 24.7%.

Assessment of thyroid hormones

Serum concentrations of maternal and cord thyroid hormones, including free T4, total T4, total T3, and TSH were measured at the central laboratory of Kaohsiung Medical University Hospital using radio-immunoassays. Commercial kits for total T3, total T4, and TSH were purchased from Daiichi Radioisotope Laboratory (Tokyo, Japan). Free T4 kits were from CIS Bio International US Inc. (Bedford, MA, USA). The intra-assay CVs of these measures were all below 5% and the inter-assay CVs were all below 10%.

Statistical analysis

The distributions of maternal PFAS concentrations were skewed; therefore, we used medians and 25th, 75th, and 95th percentiles to describe their distributions and a Spearman correlation coefficient (r) to describe the pair-wise relationships among maternal PFASs. Maternal and cord T4 concentrations were normally distributed. Maternal and cord total T3 became normally distributed after removal of a single unusually high value from each distribution. Maternal and cord free T4 and TSH were skewed. Thus we used means (standard deviation [SD]) and medians (inter-quartile range [IQR]) to describe their distributions. We compared means between two groups with Student's t-test and compared frequencies between groups with a chi-square test. For PFAS values below the LOQ, we imputed the corresponding expected value (E) conditional on

values being below LOQ based on an assumed log-normal distribution of PFASs (Richardson and Ciampi 2003) and used these when fitting models.

In preliminary analyses (not shown), we used a generalized additive model with a cubic smoothing spline to evaluate the possibility of a non-monotonic relationship between each maternal PFAS (untransformed) and each outcome; a significant spline term for a given maternal PFAS would indicate a non-linear relationship with the outcome. We did not find any significant spline terms ($p > 0.05$) in any model, therefore, we fit a linear regression model to each maternal thyroid hormone in relation to each maternal PFAS concentration and for each cord thyroid hormone and each maternal PFAS. We made no general adjustment for multiple comparisons (Rothman 1990).

In the linear regression models, thyroid hormones were the dependent variables and maternal PFASs were continuous independent variables. Thus the linear coefficient (β) corresponds to the unit change in the thyroid hormone with a one-unit (ng/mL) increase in maternal PFAS. We present results with and without natural log transformation (ln-transformation) of the thyroid hormones. Additionally, we express the estimated effect size as the ratio (%) of β to the mean thyroid hormone concentration, which can be interpreted as an index of association size.

Covariates considered were maternal age, maternal education, previous live births, family income, maternal pre-pregnancy body mass index (BMI, kg/m²), and maternal fish consumption during pregnancy. We included maternal age at enrollment (continuous) *a priori* in the models, and then we used univariate regression to identify covariates that predicted both maternal PFAS concentrations and maternal thyroid hormone concentrations with $p < 0.1$. Factors included in the final model based on this criterion were maternal education (< high school, high school, part

or full college, and > college) and previous live births (0 and ≥ 1). When we fit models between maternal PFASs and cord thyroid hormones, we also adjusted for the neonate's gender and type of delivery (normal vaginal, vacuum and caesarean section). Maternal fish consumption might be associated with both maternal PFASs and maternal thyroid hormones; however, adjustment for it may result in over-adjustment because fish are also a source of PFASs. Fish are also a source of other contaminants, such as polychlorinated biphenyls (PCBs), and iodine, both of which can affect thyroid hormone levels. Therefore, we performed sensitivity analyses by comparing results with and without adjustment for maternal fish consumption during pregnancy.

We searched for influential observations in each of the linear regression models (Belsley et al. 1980). There were few influential observations ($N < 10$) in any model and no major differences were found in the results after they were excluded. Therefore, we only present the results with all data included. SAS (Version 9.2, Cary, NC) was used to perform all statistical analysis. We considered p values < 0.05 to indicate statistical significance.

Results

Participant characteristics

The characteristics of the 285 pregnant women are shown in Table 1. They averaged 29 years old, had an average pre-pregnancy BMI of 20.6 kg/m², and generally did not smoke or consume alcohol during pregnancy. Almost all had high school education or more, and over half of the women were primiparous. The 285 subjects, compared with the 135 who had no data on PFAS and thyroid hormones, were not significantly different in age, pre-pregnancy BMI, fish consumption, previous live births or education.

Among the singleton infants delivered by these women, 116 had at least one cord serum thyroid hormone measurement (Table 1). Compared with those whose cord measurements were not available (N = 314), the distribution by gender and by type of delivery was not significantly different, nor were mean gestational weeks at birth, birth weight or maternal thyroid hormone levels (N = 169, ln-transformed). However, neonates with cord measurements had significantly higher mean maternal concentrations of PFNA (2.5 vs 1.8 ng/ml), PFUnDA (8.7 vs 5.1 ng/ml) and PFDoDA (0.44 vs 0.35 ng/ml) (ln-transformed).

Maternal PFAS and maternal and cord thyroid hormone levels

Among the nine maternal PFASs, PFHxA and PFHpA concentrations were detected in less than 20% of samples and thus were not considered further. The other seven substances were detected in more than 70% of the serum samples (Table 2). PFOS had the highest median concentration, followed by PFUnDA, PFOA, PFNA, PFHxS, PFDeA, and PFDoDA. Concentrations of PFNA, PFUnDA, and PFDoDA were highly correlated ($r \geq 0.87$, all $p < 0.001$). PFDeA concentrations were moderately correlated with concentrations of PFNA ($r = 0.62$, $p < 0.001$), PFUnDA ($r = 0.57$, $p < 0.001$), and PFDoDA ($r = 0.58$, $p < 0.001$) (see Supplemental Material, Table S1). The serum concentrations of thyroid hormones in the pregnant women and neonates are shown in Table 3. Maternal and cord total T4 and total T3 were normally distributed. The means and medians of maternal free T4, as well as cord free T4, were quite close. The distributions of both free T4 and TSH were skewed, though. As expected, cord TSH level was high, which is attributed to labor and delivery.

Association between maternal PFASs and maternal thyroid hormones

The models showed similar results before and after adjustment for covariates, therefore, the coefficients (β s) and 95% confidence intervals (CIs) are shown only after adjustment in Table 4. Most maternal PFASs were inversely associated with maternal free T4, and the associations with maternal PFNA, PFUnDA, and PFDoDA were statistically significant. According to model estimates, maternal free T4 levels decreased 0.019 ng/dL (95% CI: -0.028, -0.009) with each ng/mL increase in maternal PFNA, 0.004 ng/dL (95% CI: -0.007, -0.002) with maternal PFUnDA, and 0.132 ng/dL (95% CI: -0.204, -0.059) with maternal PFDoDA. The index of association size for free T4 per unit change in maternal PFASs is given by $\beta/\text{mean free T4} \times 100$; thus, -3.2% for maternal PFNA, -0.7% for PFNA, and -22% for PFUnDA, respectively.

Maternal PFNA, PFUnDA, and PFDoDA were also significantly inversely associated with total T4. With each ng/mL increase in maternal PFNA, PFUnDA, and PFDoDA, there was an estimated decrease of 0.189 (95% CI: -0.333, -0.046), 0.062 (95% CI: -0.097, -0.026), and 1.742 (95% CI: -2.785, -0.700) $\mu\text{g/dL}$ in maternal total T4, respectively. The index of association size was -1.7%, -0.5%, and -15.4% respectively.

We found a significant positive association between maternal PFDeA and maternal total T3, however, the magnitude was small ($\beta = 0.002$, 95% CI: 0.000, 0.003). Associations between other maternal PFASs and maternal total T3 were very small and not statistically significant. Maternal PFHxS was positively associated with maternal TSH levels with statistical significance. There was an estimated increase of 0.105 (95% CI: 0.002, 0.207) $\mu\text{IU/ml}$ in maternal TSH levels with each ng/mL increase in maternal PFHxS. The index of association size was a 5.2% increase in maternal TSH per ng/mL increase in maternal PFHxS.

Results for ln-transformed maternal thyroid hormones are presented in the Supplemental Material, Table S2. There were no differences in the direction or significance of the observed associations between the analyses using transformed or untransformed thyroid hormone values. In the sensitivity analysis, adjustment for maternal fish consumption did not change the results for either maternal or cord thyroid hormones (data not shown).

Association between maternal PFASs and cord thyroid hormones

We also investigated the associations between maternal PFASs and cord thyroid hormones (Table 5). Maternal PFNA, PFUnDA and PFDoDA levels were also inversely associated with cord total T4. The cord total T4 level decreased 0.213 (95% CI: -0.384, -0.042) ng/dL with each ng/mL increase in maternal PFNA, 0.052 (95% CI: -0.095, -0.010) ng/dL with each ng/mL increase in PFUnDA, and 1.92 (95% CI: -3.345, -0.495) ng/dL with each ng/mL increase in PFDoDA. The index of association size was -2.5%, -0.6 %, and -23% with each ng/mL increase in maternal PFNA, PFDoDA and PFUnDA, respectively.

Additionally, these three substances were also inversely associated with cord total T3 levels. With each ng/mL increase in maternal PFNA, PFUnDA, and PFDoDA, there was a decrease of 0.002 (95% CI: -0.004, -0.001), 0.001 (95% CI: -0.001, -0.0002), 0.022 (95% CI: -0.035, -0.009) µg/dL in cord total T3, respectively. The index of association size was -3.3%, -1.7 %, and -0.3% respectively. Higher maternal PFDeA concentrations were also significantly associated with lower cord total T3. One ng/ml increase in PFDeA was associated with a 0.017 (95% CI: -0.028, -0.005) decrease in cord total T3. The index of association size was 24%.

Associations between maternal PFNA and cord total T4, and maternal PFUnDA and cord total T4 were still negative but lost statistical significance after further adjustment for fish

consumption (data not shown), while other associations were similar to those without adjustment for fish consumption. Results for ln-transformed cord thyroid hormones were similar (see Supplemental Material, Table S3).

Discussion

In these data, maternal serum concentrations of three PFASs - PFNA, PFUnDA and PFDoDA - were strongly correlated. All three were significantly inversely associated with maternal free T4 and total T4, and with cord total T3 and total T4. Additionally, we found a statistically significant positive association between maternal serum concentrations of PFHxS and maternal TSH levels, and a significant positive association of maternal PFDeA with maternal total T3, but inverse association between maternal PFDeA and cord total T3 levels.

The inverse associations we observed between maternal PFNA, PFUnDA and PFDoDA and maternal free T4 and total T4, and cord total T3 and total T4 have not been reported before. A study done in South Korea, where pregnant women were recruited from three hospitals in large cities and their blood samples (N = 44) were collected in the 3rd trimester and from the cord at delivery, reported inverse associations between maternal PFOS and cord T3 levels, and between maternal PFTrDA and cord T4 and T3 (Kim et al. 2011). However, we did not find the significant adverse association between maternal PFOS and cord T3. As we did not measure maternal PFTrDA, we could not replicate that finding. In non-pregnant women, some PFASs were found to be associated with elevated T4 (Dallaire et al. 2009; Knox et al. 2011).

We found a significant positive association between maternal PFDeA and maternal total T3, but it was small ($\beta = 0.002$). The association between maternal PFDeA and cord total T3 was negative, which is consistent with the inverse associations between maternal PFNA, PFUnDA,

and PFDoDA and thyroid hormones in both maternal and cord serum. Thus, we believe the positive association is likely due to chance.

A reduction in serum T4 level can cause a feedback elevation of TSH level. We observed positive associations between maternal PFNA, PFUnDA and PFDoDA and maternal TSH, although non-significant. However, there was a positive association between maternal PFHxS and maternal TSH, and adverse, though non-significant, associations between maternal PFHxS and maternal free T4 or total T4. In the study of Korean women conducted by Kim et al., there was a positive correlation between maternal PFOA and cord TSH levels (Kim et al. 2011). In the two available rodent studies, no significant changes in serum TSH levels were detected among pregnant rats treated with PFOS (Lau et al. 2003) or among PFOS-exposed pups (Thibodeaux et al. 2003) despite decreases in total T4 in both studies. However, Luebker et al. reported higher serum TSH in association with lower T4 among rat pups from PFOS treated dams (Luebker et al. 2003), and Seacat et al. also found an increase in serum TSH among both male and non-pregnant female monkeys with treatment of PFOS (Seacat et al. 2002).

To our knowledge, there are no studies in experimental animals on the mechanism by which PFNA, PFUnDA and PFDoDA might modify thyroid hormones. However, investigations have been carried out for PFOS in rats. PFOS caused a reduction in both total T4 and free T4 levels in pregnant rats, in a protocol with daily dosing from gestational day 2 to day 20 (Thibodeaux et al. 2003). In another study, a single dose of 15 mg of PFOS (producing a concentration in serum of approximately 50 - 75 µg/mL) lowered total T3 and total T4 (Chang et al. 2008). It was hypothesized that PFOS competed with free T4 for binding sites on the thyroid hormone transport protein transthyretin (TTR) in rats, which may have resulted in a lowering of serum

total T3 and total T4 (Chang et al. 2008). Such competitive displacement may also occur in humans, a suggestion supported by an *in vitro* study in which PFASs exhibited binding potency with human TTR (Weiss et al. 2009). However, different PFASs showed different binding. PFNA, PFUnDA and PFDoDA showed less binding strength than PFOS and PFOA (Weiss et al. 2009). This indicates that protein binding is probably not the sole factor contributing to the variation in associations of PFASs with thyroid hormones.

Besides affecting thyroid hormone transport, PFASs may also alter thyroid hormones biosynthesis and metabolism. In Yu et al.'s study, hepatic uridine diphosphoglucuronosyl transferase 1A1 (UGT1A1) activity, which is involved in hepatic metabolism of thyroid hormones, was induced in PFOS exposed rats and subsequently led to glucuronidation of T4 and circulating T4 deficiency (Yu et al. 2009). Apart from UGT1A1, they also found that PFOS increased thyroidal conversion of T4 to T3 via type 1 deiodinase, which was also a contribution to the reduction in T4 (Yu et al. 2009). It should be noted that the PFAS concentrations in treated rats were much higher than seen in the general population of humans.

The median serum concentrations of long-chain PFASs, PFNA, PFUnDA, and PFDoDA were slightly higher in our Taiwan study population than reported for study populations in western countries (Calafat et al. 2007; Gutzkow et al. 2012), but comparable to levels found in populations from Japan, Korea, and Vietnam (Harada et al. 2011). However, two other studies from Taiwan reported much higher concentrations than we observed (Lien et al. 2011; Lin et al. 2012), suggesting that local or regional sources of exposure may be important in Taiwan. Additionally, concentrations of maternal PFNA, PFUnDA, and PFDoDA were strongly correlated, indicating that these substances may have common sources of exposure. Because these are longer chain PFASs, which are considered more bio-accumulative and toxic than

shorter PFASs (Goecke-Flora and Reo 1996; Kudo et al. 2001), investigation is needed on their sources, routes of exposures, and any resulting toxicity.

We had only one maternal serum sample and one cord serum sample (representing the infant), with which to assess both exposure and outcome. This leads to the question of whether these samples allow any reasonable inferences. In another population of Danish pregnant women, concentrations of PFOS and PFOA in samples drawn in the 1st and 2nd trimester are highly correlated (both 0.9) (Fei et al. 2007). Concentrations do decline over the course of pregnancy, but our samples were all drawn in a single (the 3rd) trimester. If the other PFASs behave like PFOS and PFOA, it seems reasonable to regard women with higher concentrations in the samples we have as being more highly exposed. For the maternal outcomes, total T3 and total T4 are higher during pregnancy and increase over its course; free T4 is lower and decreases somewhat; the range of TSH is about the same for pregnant and non-pregnant women (Soldin et al. 2004). Variability in a given woman over the course of pregnancy is reported to be smaller than the variability between women (Boas et al. 2009), and thus the concentration in a given sample can be viewed as more representative of the individual from whom it was drawn rather than the trimester in which it was drawn. Thus, while samples drawn at multiple times might be better, using the sample at a given time during pregnancy does not appear likely to produce spurious associations; it would likely decrease power and attenuate measures of association.

T3 and T4 increase over gestation, but free T4 is stable. Cord blood at term can have the highest T4 experienced by the fetus, since TSH normally falls after birth. There is generally not good correlation between T4, T3, or TSH in cord serum and maternal serum at term; this is thought to result from the increasing autonomy of the fetal thyroid axis as the pregnancy proceeds (Hume et al. 2004). Thus, any biological basis for the associations we see with thyroid hormones in cord

serum and maternal PFASs should reflect effects on the fetus, rather than on the mother. Measurement of infant thyroid hormones shortly after birth might have been more informative, as they are less affected by perturbations associated with delivery.

The main strength of the present study was having data for both a panel of PFASs and thyroid hormones. Yet some limitations should be noted. First, although our study was relatively large, the size was not sufficient to evaluate clinical outcomes such as hypothyroidism or hypothyroxinemia. Second, three of the substances, PFNA, PFUnDA and PFDoDA, were highly correlated, thus we were unable to distinguish their independent associations. Third, many factors can affect thyroid hormone levels, such as iodine status, thyroid antibodies, etc., and we did not have measurements of all of them. Finally, some aspects of this study were cross-sectional, making the direction of causation uncertain.

In conclusion, thyroid hormones are of critical importance to both pregnant women and their offspring. Decreased maternal provision of T4 to the fetus leads to an increased risk of poor cognition, behavior and growth (Idris et al. 2005; Sahu et al. 2010). PFASs have been reported to be associated with low birth weight (Maisonet et al. 2012; Washino et al. 2009) and developmental problems in childhood (Hoffman et al. 2010), which might be due in part to disruption of thyroid hormone homeostasis. Our findings suggest maternal PFAS exposure may interfere with both maternal and fetal thyroid hormone homeostasis. The ubiquity of PFASs and the critical role of thyroid hormones in fetal growth and neurodevelopment make the findings of potentially great public health importance.

References

- Andersen ME, Butenhoff JL, Chang SC, Farrar DG, Kennedy GL, Jr., Lau C, et al. 2008. Perfluoroalkyl acids and related chemistries--toxicokinetics and modes of action. *Toxicol Sci* 102:3-14.
- Boas M, Forman JL, Juul A, Feldt-Rasmussen U, Skakkebaek NE, Hilsted L, et al. 2009. Narrow intra-individual variation of maternal thyroid function in pregnancy based on a longitudinal study on 132 women. *Eur J Endocrinol* 161:903-910.
- Belsley DA, Kuh E, Welsh RE. 1980. *Regression diagnostics: Identifying influential data and sources of collinearity*. New York: John Wiley & Sons.
- Calafat AM, Wong LY, Kuklennyik Z, Reidy JA, Needham LL. 2007. Polyfluoroalkyl chemicals in the U.S. Population: Data from National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. *Environ Health Perspect* 115:1596-1602.
- Chan E, Burstyn I, Cherry N, Bamforth F, Martin JW. 2011. Perfluorinated acids and hypothyroxinemia in pregnant women. *Environ Res* 111:559-564.
- Chang SC, Thibodeaux JR, Eastvold ML, Ehresman DJ, Bjork JA, Froehlich JW, et al. 2008. Thyroid hormone status and pituitary function in adult rats given oral doses of perfluorooctanesulfonate (PFOS). *Toxicology* 243:330-339.
- Contempre B, Jauniaux E, Calvo R, Jurkovic D, Campbell S, de Escobar GM. 1993. Detection of thyroid hormones in human embryonic cavities during the first trimester of pregnancy. *J Clin Endocrinol Metab* 77:1719-1722.
- Dallaire R, Dewailly E, Pereg D, Dery S, Ayotte P. 2009. Thyroid function and plasma concentrations of polyhalogenated compounds in Inuit adults. *Environ Health Perspect* 117:1380-1386.
- Fei C, McLaughlin JK, Tarone RE, Olsen J. 2007. Perfluorinated chemicals and fetal growth: A study within the Danish national birth cohort. *Environ Health Perspect* 115:1677-1682.
- Fisher DA. 1997. Fetal thyroid function: Diagnosis and management of fetal thyroid disorders. *Clin Obstet Gynecol* 40:16-31.

- Fromme H, Tittlemier SA, Volkel W, Wilhelm M, Twardella D. 2009. Perfluorinated compounds--exposure assessment for the general population in western countries. *Int J Hyg Environ Health* 212:239-270.
- Goecke-Flora CM, Reo NV. 1996. Influence of carbon chain length on the hepatic effects of perfluorinated fatty acids. A ¹⁹F- and ³¹P-NMR investigation. *Chem Res Toxicol* 9:689-695.
- Harada KH, Hitomi T, Niisoe T, Takanaka K, Kamiyama S, Watanabe T, et al. 2011. Odd-numbered perfluorocarboxylates predominate over perfluorooctanoic acid in serum samples from Japan, Korea and Vietnam. *Environ Int* 37:1183-1189.
- Hoffman K, Webster TF, Weisskopf MG, Weinberg J, Vieira VM. 2010. Exposure to polyfluoroalkyl chemicals and attention deficit/hyperactivity disorder in U.S. children 12-15 years of age. *Environ Health Perspect.* 118:1762-1767.
- Houde M, Martin JW, Letcher RJ, Solomon KR, Muir DC. 2006. Biological monitoring of polyfluoroalkyl substances: A review. *Environ Sci Technol* 40:3463-3473.
- Hume R, Simpson J, Delahunty C, van Toor H, Wu SY, Williams FL, et al. 2004. Human fetal and cord serum thyroid hormones: developmental trends and interrelationships. *J Clin Endocrinol Metab* 89:4097-4103.
- Idris I, Srinivasan R, Simm A, Page RC. 2005. Maternal hypothyroidism in early and late gestation: effects on neonatal and obstetric outcome. *Clin Endocrinol (Oxf)* 63:560-565.
- Kim S, Choi K, Ji K, Seo J, Kho Y, Park J, et al. 2011. Trans-placental transfer of thirteen perfluorinated compounds and relations with fetal thyroid hormones. *Environ Sci Technol* 45:7465-7472.
- Knox SS, Jackson T, Frisbee SJ, Javins B, Ducatman AM. 2011. Perfluorocarbon exposure, gender and thyroid function in the C8 health project. *J Toxicol Sci* 36:403-410.
- Kudo N, Suzuki E, Katakura M, Ohmori K, Noshiro R, Kawashima Y. 2001. Comparison of the elimination between perfluorinated fatty acids with different carbon chain length in rats. *Chem Biol Interact* 134:203-216.
- Lau C, Thibodeaux JR, Hanson RG, Rogers JM, Grey BE, Stanton ME, et al. 2003. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. II: postnatal evaluation. *Toxicol Sci* 74:382-392.

- Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. 2007. Perfluoroalkyl acids: a review of monitoring and toxicological findings. *Toxicol Sci* 99:366-394.
- Lien GW, Wen TW, Hsieh WS, Wu KY, Chen CY, Chen PC. 2011. Analysis of perfluorinated chemicals in umbilical cord blood by ultra-high performance liquid chromatography/tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 879:641-646.
- Lin CY, Wen LL, Lin LY, Wen TW, Lien GW, Hsu SH, et al. 2013. The associations between serum perfluorinated chemicals and thyroid function in adolescents and young adults. *J Hazard Mater* 244-245: 637-644.
- Luebker DJ, York RG, Hansen KJ, Moore JA, Butenhoff JL. 2005. Neonatal mortality from in utero exposure to perfluorooctanesulfonate (PFOS) in sprague-dawley rats: dose-response, and biochemical and pharmacokinetic parameters. *Toxicology* 215:149-169.
- Maisonet M, Terrell ML, McGeehin MA, Christensen KY, Holmes A, Calafat AM, et al. 2012. Maternal concentrations of polyfluoroalkyl compounds during pregnancy and fetal and postnatal growth in British girls. *Environ Health Perspect* 120:1432-1437.
- Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, et al. 2007. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. *Environmental health perspectives* 115:1298-1305.
- Richardson DB, Ciampi A. 2003. Effects of exposure measurement error when an exposure variable is constrained by a lower limit. *Am J Epidemiol* 157:355-363.
- Rothman KJ. 1990. No adjustments are needed for multiple comparisons. *Epidemiology (Cambridge, Mass)* 1:43-46.
- Sahu MT, Das V, Mittal S, Agarwal A, Sahu M. 2010. Overt and subclinical thyroid dysfunction among Indian pregnant women and its effect on maternal and fetal outcome. *Arch Gynecol Obstet* 281:215-220.
- Seacat AM, Thomford PJ, Hansen KJ, Olsen GW, Case MT, Butenhoff JL. 2002. Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. *Toxicol Sci* 68:249-264.

- Soldin OP, Tractenberg RE, Hollowell JG, Jonklaas J, Janicic N, Soldin SJ. 2004. Trimester-specific changes in maternal thyroid hormone, thyrotropin, and thyroglobulin concentrations during gestation: trends and associations across trimesters in iodine sufficiency. *Thyroid* 14:1084-1090.
- Thibodeaux JR, Hanson RG, Rogers JM, Grey BE, Barbee BD, Richards JH, et al. 2003. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I: maternal and prenatal evaluations. *Toxicol Sci* 74:369-381.
- Vulsma T, Gons MH, de Vijlder JJ. 1989. Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. *N Engl J Med* 321:13-16.
- Washino N, Saijo Y, Sasaki S, Kato S, Ban S, Konishi K, et al. 2009. Correlations between prenatal exposure to perfluorinated chemicals and reduced fetal growth. *Environ Health Perspect* 117:660-667.
- Weiss JM, Andersson PL, Lamoree MH, Leonards PE, van Leeuwen SP, Hamers T. 2009. Competitive binding of poly- and perfluorinated compounds to the thyroid hormone transport protein transthyretin. *Toxicol Sci* 109:206-216.
- Yu WG, Liu W, Jin YH. 2009. Effects of perfluorooctane sulfonate on rat thyroid hormone biosynthesis and metabolism. *Environ Toxicol Chem / SETAC* 28:990-996.

Table 1. Characteristics of the pregnant women (N = 285) and neonates (N = 116).

Characteristics	Mean ± SD or %
Maternal age at enrollment (years), mean ± SD	28.8 ± 4.3
Maternal weight (kg), mean ± SD	52.3 ± 7.7
Maternal height (m), mean ± SD	159.2 ± 4.7
Maternal pre-pregnancy BMI (kg/m ²), mean ± SD	20.6 ± 2.9
Maternal fish consumption (times/week), median (IQR)	3.8 (1.9, 6.8)
Maternal previous live births, N (%)	
0	162 (57.0)
≥ 1	123 (43.0)
Maternal smoking during pregnancy, N (%)	(1.4)
Maternal drinking alcohol during pregnancy, N (%)	(0.7)
Maternal education, N (%)	
< High school	16 (5.6)
High school	127 (44.4)
Part or full college	100 (35.2)
> College	42(14.8)
Maternal annual family income (US \$), N (%)	
< 13, 771	42 (15.1)
≥ 13, 771 - <20, 672	84 (30.1)
≥ 20, 672 - <34, 453	111 (39.4)
≥ 34, 453	43 (15.4)
Neonatal gender, N (%)	
Female	59 (50.9)
Male	57(49.1)
Neonatal type of delivery, N (%)	
Normal vaginal	40 (34.5)
Vacuum	42 (36.2)
Caesarean section	34 (29.3)
Neonatal gestational weeks at birth, mean ± SD	38.8 ± 1.6
Neonatal birth weight (kg), mean ± SD	3.2 ± 0.4

Abbreviations: BMI, body mass index; IQR, inter-quartile range; SD, standard deviation.

Table 2. Serum concentrations of maternal PFASs (ng/mL).

Maternal PFASs (N = 285)	Molecular Formula	% > LOQ	25th percentile	Median	75th percentile	95th percentile
Perfluorohexanesulfonic acid (PFHxS)	C ₅ F ₁₃ CSO ₃ H	78	0.30	0.81	1.35	2.90
Perfluorooctanoic acid (PFOA)	C ₇ F ₁₅ CO ₂ H	87	1.54	2.39	3.40	5.20
Perfluorooctane sulfonate (PFOS)	C ₇ F ₁₇ CSO ₃ H	100	9.65	12.73	17.48	27.85
Perfluorononanoic acid (PFNA)	C ₈ F ₁₇ CO ₂ H	96	0.85	1.51	2.51	6.20
Perfluorodecanoic acid (PFDeA)	C ₉ F ₁₉ CO ₂ H	71	0.10	0.46	0.69	1.09
Perfluoroundecanoic acid (PFUnDA)	C ₁₀ F ₂₁ CO ₂ H	91	1.70	3.26	9.20	22.05
Perfluorododecanoic acid (PFDoDA)	C ₁₁ F ₂₃ CO ₂ H	82	0.23	0.36	0.53	0.85

Abbreviations: PFASs, perfluoroalkyl substances; LOQ, limit of quantification.

Table 3. Serum concentrations of maternal and cord thyroid hormones.

Sample	Free T4 (ng/dL)	Total T4 (µg/dL)	Total T3 (µg/dL)	TSH (µIU/mL)
Pregnant women				
N	285	274	276	283
Mean ± SD	0.60 ± 0.2	11.29 ± 2.3	0.16 ± 0.04	2.03 ± 1.3
Median (IQR)	0.57 (0.49, 0.69)	11.16 (9.70, 12.80)	0.16 (0.13, 0.18)	1.76 (1.19, 2.45)
Cord				
N	92	116	112	114
Mean ± SD	0.74 ± 0.2	8.36 ± 2.0	0.06 ± 0.02	9.00 ± 6.9
Median (IQR)	0.73 (0.60, 0.88)	8.37 (6.80, 9.80)	0.05 (0.046, 0.066)	6.65 (4.60, 11.00)

Abbreviations: IQR, inter-quartile range; SD, standard deviation; T3, triiodothyronine; T4, thyroxin; TSH, thyroid stimulating hormone.

Table 4. Linear regression coefficients (95 % CI) for associations between maternal PFASs and maternal thyroid hormones. ^a

Maternal PFAS^b	Free T4 (N = 285)	Total T4 (N = 274)	Total T3 (N = 276)	TSH (N = 283)
PFHxS	-0.010 (-0.023, 0.003)	-0.130 (-0.316, 0.057)	-0.002 (-0.005, 0.001)	0.105 (0.002, 0.207)*
PFOA	-0.003 (-0.012, 0.005)	0.011 (-0.108, 0.130)	-0.000 (-0.002, 0.009)	0.011 (-0.057, 0.078)
PFOS	0.001 (-0.002, 0.003)	0.019 (-0.016, 0.053)	0.000 (-0.002, 0.001)	-0.005 (-0.024, 0.013)
PFNA	-0.019 (-0.028, -0.009)***	-0.189 (-0.333, -0.046)**	-0.001 (-0.003, 0.002)	0.033 (-0.046, 0.112)
PFDeA	-0.001 (-0.006, 0.005)	0.047 (-0.028, 0.123)	0.002 (0.000, 0.003)**	0.004 (-0.037, 0.045)
PFUnDA	-0.004 (-0.007, -0.002)***	-0.062 (-0.097, -0.026)***	-0.000 (-0.001, 0.000)	0.011 (-0.009, 0.030)
PFDoDA	-0.132 (-0.204, -0.059)***	-1.742 (-2.785, -0.700)**	-0.005 (-0.022, 0.011)	0.365 (-0.215, 0.944)

Abbreviations: CI, confidence interval; PFHxS, perfluorohexanesulfonic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate; PFNA, perfluorononanoic acid; PFDeA, perfluorodecanoic acid; PFUnDA, perfluoroundecanoic acid; PFDoDA, perfluorododecanoic acid; T3, triiodothyronine; T4, thyroxin; TSH, thyroid stimulating hormone. Units of PFASs are in ng/mL. The unit of TSH is μ IU/mL, units of free T4 and total T3 are ng/dL and the unit of total T4 is μ g/dL.

^aModels were adjusted for maternal age, maternal education levels and maternal previous live births. ^bValues below LOQ were imputed based on expected values assuming a log-normal distribution.

* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

Table 5. Linear regression coefficients (95 % CI) for associations between maternal PFASs and cord thyroid hormones. ^a

Maternal PFAS^b	Free T4 (N = 92)	Total T4 (N = 116)	Total T3 (N = 112)	TSH (N = 114)
PFHxS	-0.030 (-0.098, 0.039)	0.002 (-0.495, 0.500)	-0.001 (-0.007, 0.004)	0.493 (-1.449, 2.434)
PFOA	-0.029 (-0.062, 0.004)	0.128 (-0.094, 0.350)	-0.001 (-0.004, 0.001)	-0.498 (-1.464, 0.468)
PFOS	0.001 (-0.006, 0.008)	0.032 (-0.024, 0.087)	0.000 (-0.000, 0.001)	-0.083 (-0.292, 0.127)
PFNA	0.001 (-0.021, 0.023)	-0.213 (-0.384, -0.042) *	-0.002 (-0.004, -0.001)**	-0.361 (-0.955, 0.234)
PFDeA	0.020 (-0.124, 0.164)	-0.513 (-1.732, 0.706)	-0.017 (-0.028, -0.005)**	-3.505 (-7.821, 0.812)
PFUnDA	0.002 (-0.004, 0.007)	-0.052 (-0.095, -0.010) *	-0.001 (-0.001, -0.0002)**	-0.083 (-0.232, 0.066)
PFDODA	-0.009 (-0.183, 0.165)	-1.920 (-3.345, -0.495) **	-0.022 (-0.035, -0.009)**	-1.539 (-6.582, 3.503)

Abbreviations: CI, confidence interval; PFHxS, perfluorohexanesulfonic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate; PFNA, perfluorononanoic acid; PFDeA, perfluorodecanoic acid; PFUnDA, perfluoroundecanoic acid; PFDODA, perfluorododecanoic acid; T3, triiodothyronine; T4, thyroxine; TSH, thyroid stimulating hormone. Units of PFASs are in ng/mL. Unit of TSH is μ IU/mL. Units of free T4 and total T3 are ng/dL and unit of total T4 is μ g/dL.

^aAdjusted for maternal age, maternal education levels, maternal previous children, neonatal gender and neonatal type of delivery.

^bValues below LOQ were imputed based on expected values assuming a log-normal distribution.

* $p < 0.05$; ** $p < 0.01$.